148 related articles for article (PubMed ID: 36565374)
1. Individual Case Safety Report Replication: An Analysis of Case Reporting Transmission Networks.
van Stekelenborg J; Kara V; Haack R; Vogel U; Garg A; Krupp M; Gofman K; Dreyfus B; Hauben M; Bate A
Drug Saf; 2023 Jan; 46(1):39-52. PubMed ID: 36565374
[TBL] [Abstract][Full Text] [Related]
2. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
3. Sorting Through the Safety Data Haystack: Using Machine Learning to Identify Individual Case Safety Reports in Social-Digital Media.
Comfort S; Perera S; Hudson Z; Dorrell D; Meireis S; Nagarajan M; Ramakrishnan C; Fine J
Drug Saf; 2018 Jun; 41(6):579-590. PubMed ID: 29446035
[TBL] [Abstract][Full Text] [Related]
4. Development of a checklist for the assessment of pharmacovigilance guidelines in Southern Africa: a document review.
Makhene NL; Steyn H; Vorster M; Lubbe MS; Burger JR
Ther Adv Drug Saf; 2023; 14():20420986221143272. PubMed ID: 36713000
[TBL] [Abstract][Full Text] [Related]
5. Automation Opportunities in Pharmacovigilance: An Industry Survey.
Ghosh R; Kempf D; Pufko A; Barrios Martinez LF; Davis CM; Sethi S
Pharmaceut Med; 2020 Feb; 34(1):7-18. PubMed ID: 32036574
[TBL] [Abstract][Full Text] [Related]
6. Rates of spontaneous reports of adverse drug reactions for drugs reported in children: a cross-sectional study with data from the Swedish adverse drug reaction database and the Swedish Prescribed Drug Register.
Wallerstedt SM; Brunlöf G; Sundström A
Drug Saf; 2011 Aug; 34(8):669-82. PubMed ID: 21751827
[TBL] [Abstract][Full Text] [Related]
7. An Evaluation of Postmarketing Reports with an Outcome of Death in the US FDA Adverse Event Reporting System.
Marwitz K; Jones SC; Kortepeter CM; Dal Pan GJ; Muñoz MA
Drug Saf; 2020 May; 43(5):457-465. PubMed ID: 31981082
[TBL] [Abstract][Full Text] [Related]
8. Towards Automating Adverse Event Review: A Prediction Model for Case Report Utility.
Muñoz MA; Dal Pan GJ; Wei YJ; Delcher C; Xiao H; Kortepeter CM; Winterstein AG
Drug Saf; 2020 Apr; 43(4):329-338. PubMed ID: 31912439
[TBL] [Abstract][Full Text] [Related]
9. Pediatric Drug Safety Surveillance in FDA-AERS: A Description of Adverse Events from GRiP Project.
de Bie S; Ferrajolo C; Straus SM; Verhamme KM; Bonhoeffer J; Wong IC; Sturkenboom MC;
PLoS One; 2015; 10(6):e0130399. PubMed ID: 26090678
[TBL] [Abstract][Full Text] [Related]
10. Development of a multivariate prediction model to identify individual case safety reports which require clinical review.
Gosselt HR; Bazelmans EA; Lieber T; van Hunsel FPAM; Härmark L
Pharmacoepidemiol Drug Saf; 2022 Dec; 31(12):1300-1307. PubMed ID: 36251280
[TBL] [Abstract][Full Text] [Related]
11. A Risk-Based Approach for Safety Case Follow-up of Adverse Event Reports in Pharmacovigilance.
Vemula GK; Badale P; Mavrogenis P; Lalande-Luesink I; Borkowski M; Lewis DJ
Adv Ther; 2024 Jan; 41(1):82-91. PubMed ID: 37919600
[TBL] [Abstract][Full Text] [Related]
12. Pharmacovigilance in Israel - tools, processes, and actions.
Schwartzberg E; Berkovitch M; Dil Nahlieli D; Nathan J; Gorelik E
Isr J Health Policy Res; 2017 Aug; 6(1):29. PubMed ID: 28760141
[TBL] [Abstract][Full Text] [Related]
13. Drug-induced liver injury in Switzerland: an analysis of drug-related hepatic disorders in the WHO pharmacovigilance database VigiBase from 2010 to 2020.
Ortland I; Mirjalili M; Kullak-Ublick GA; Peymani P
Swiss Med Wkly; 2021 May; 151():w20503. PubMed ID: 34000058
[TBL] [Abstract][Full Text] [Related]
14. Adverse Drug Reaction Case Safety Practices in Large Biopharmaceutical Organizations from 2007 to 2017: An Industry Survey.
Stergiopoulos S; Fehrle M; Caubel P; Tan L; Jebson L
Pharmaceut Med; 2019 Dec; 33(6):499-510. PubMed ID: 31933240
[TBL] [Abstract][Full Text] [Related]
15. Leveraging Case Narratives to Enhance Patient Age Ascertainment from Adverse Event Reports.
Pham P; Cheng C; Wu E; Kim I; Zhang R; Ma Y; Kortepeter CM; Muñoz MA
Pharmaceut Med; 2021 Sep; 35(5):307-316. PubMed ID: 34476768
[TBL] [Abstract][Full Text] [Related]
16. Adverse Drug Reaction Reporting in Africa and a Comparison of Individual Case Safety Report Characteristics Between Africa and the Rest of the World: Analyses of Spontaneous Reports in VigiBase®.
Ampadu HH; Hoekman J; de Bruin ML; Pal SN; Olsson S; Sartori D; Leufkens HG; Dodoo AN
Drug Saf; 2016 Apr; 39(4):335-45. PubMed ID: 26754924
[TBL] [Abstract][Full Text] [Related]
17. Identification of Substandard Medicines via Disproportionality Analysis of Individual Case Safety Reports.
Trippe ZA; Brendani B; Meier C; Lewis D
Drug Saf; 2017 Apr; 40(4):293-303. PubMed ID: 28130773
[TBL] [Abstract][Full Text] [Related]
18. An analysis of the trends, characteristics, scope, and performance of the Zimbabwean pharmacovigilance reporting scheme.
Masuka JT; Khoza S
Pharmacol Res Perspect; 2020 Oct; 8(5):e00657. PubMed ID: 32930524
[TBL] [Abstract][Full Text] [Related]
19. Key elements in adverse drug interaction safety signals: an assessment of individual case safety reports.
Strandell J; Norén GN; Hägg S
Drug Saf; 2013 Jan; 36(1):63-70. PubMed ID: 23315297
[TBL] [Abstract][Full Text] [Related]
20. Pharmacovigilance activities in ASEAN countries.
Suwankesawong W; Dhippayom T; Tan-Koi WC; Kongkaew C
Pharmacoepidemiol Drug Saf; 2016 Sep; 25(9):1061-9. PubMed ID: 27174034
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]